Skip to content
POM-V Prescription Required

Equip FT Suspension for Injection

Active ingredients: Equine influenza virus, Tetanus toxoid, immunopurified (IPTT)

Form

Injection

Species

Horses

Manufacturer

Zoetis UK Limited

VMD MA No.

42058/5163

What it's used for

Onset of immunity: within 2 weeks of completion of the primary course. Duration of immunity: 1 year and 3 months for influenza and 3 years for tetanus.

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Equine influenza virus + Tet...

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Equip FT Suspension for Injection — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Onset of immunity: within 2 weeks of completion of the primary course.
Duration of immunity: 1 year and 3 months for influenza and 3 years for tetanus.
AN: 04278/2024 and AN: 01668/2025
Vaccination schedule
medicinal product should be used as follows:
Primary course
6 week interval
Second dose EQUIP FT
5 month interval
Boosters
12-15 month interval
2nd booster EQUIP F
12-15 month interval
3rd booster EQUIP FT
Thereafter, booster doses of Equip FT or Equip F should be administered so that the
interval between vaccinations against influenza is not more than 15 months and the interval
between vaccinations against tetanus is not more than 36 months.
Note: The routine practice of administering booster doses annually may remain the most
convenient, even though protection against equine influenza has been demonstrated by
challenge studies 15 months following the third vaccination (first booster dose). No field
challenge studies have been carried out prior to the third vaccination; instead, efficacy was
evaluated by serology which showed titres equivalent to those found in horses protected
against challenge at 15 months.
It is recommended that a single booster dose should only be administered to horses that
have already received a full primary course using vaccines that contain the same types of
equine influenza virus included in this vaccine. A full primary course may be considered
necessary in horses that have not been suitably primed.
None.
Horses:
Rare
(1 to 10 animals / 10,000 animals
treated):
Injection site swelling
1,3
Stiffness
Elevated temperature
1,2
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Injection site pain
Hypersensitivity reaction
Anorexia, Lethargy
This condition normally resolves by the day following vaccination.
Mild, transient, typically 9-12 hours post vaccination.
Local, small (10-20 mm in diameter), soft, non-painful.
In the event of an allergic or anaphylactic reaction, immediate treatment should be given
with a soluble glucocorticoid intravenously or adrenalin intramuscularly.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary
medicinal product. Reports should be sent, preferably via a veterinarian, to either the
marketing authorisation holder or the national competent authority via the national reporting
system. See the package leaflet for respective contact details.
Vaccinate healthy animals only.
The efficacy of active immunisation of young foals against equine influenza and tetanus will
be influenced by the level of maternally derived antibodies. This will vary between
individuals due to a number of factors, e.g. the immune status of the dam, adequacy of
colostrum intake by the foal, etc. The vaccine should not be used in foals below 5 months of
age, and foals should not be vaccinated until maternally derived antibodies have fallen
below protective levels.
In any animal population, there may be a small number of individuals which fail to respond
fully to vaccination. Successful vaccination depends upon correct storage and
administration of the vaccine and the ability of the animal to respond. This can be influenced
by such factors as genetic constitution, intercurrent infection, age, nutritional status,
concurrent drug therapy and stress.

Special precautions for safe use in the target species:
Not applicable.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
In case of accidental self-injection, seek medical advice immediately and show the package
leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.
AN: 04278/2024 and AN: 01668/2025
No information is available on the safety and efficacy of this vaccine when used with any
other veterinary medicinal product. A decision to use this vaccine before or after any other
veterinary medicinal product therefore needs to be made on a case-by-case basis.
Store in a refrigerator (2 C - 8 C).
Protect from light.
Do not freeze.
Keep the container in the outer carton.
Zero days.
AN: 04278/2024 and AN: 01668/2025

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.